Form 4 for TNYA Tenaya Therapeutics, Inc.
Accepted 2025-11-17 00:00:00 ET · period of report 2025-11-17 · accession 0001193125-25-284996 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-17 | 2025-11-17 | TNYA | Ali Faraz | CEO, Dir | S - Sale | $1.33 | -3,126 | 299.7K | -1% | -$4,158 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-17 | S | D | 3,126 | $1.33 | 299,666 | D | — | — | (F2) Includes 211,275 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. |